Chinese Biotech Innovation Poses New Risks for U.S.-Listed Companies
U.S. biotech firms are increasingly licensing drug candidates developed in China, raising concerns about the risks of relying on foreign innovation. Jefferies estimates that nearly a third of industry licensing spending went to Chinese-origin drugs in 2025.
Tickers: $SMMT
Topics: biotechnology China-US innovation shift investment risks licensing deals